Navigation Links
Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
Date:3/10/2008

Company to host conference call Today, Monday, March 10, 2008 at 8:30am

NEW YORK, March 10 /PRNewswire-FirstCall/ -- On Friday, March 7, 2008, Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), announced top-line results from its SUN-MICRO Phase 3 clinical trial of Sulonex (sulodexide) for the treatment of diabetic nephropathy. The Company announced that this Phase 3 clinical trial failed to meet the primary objective of the study, which was to increase the proportion of patients that achieve therapeutic success at 6 months as compared to placebo over background therapy of maximal doses of ACE-inhibitors or ARBs. Therapeutic success was defined as (i) conversion from microalbuminuria to normoalbuminuria, as measured by albumin/creatinine ratio (ACR), with at least a 25% reduction in ACR relative to baseline ACR, or (ii) a 50% reduction in ACR relative to baseline ACR. In addition, in reviewing the mean changes in ACR over time, Sulonex and placebo appeared to be similar.

Michael S. Weiss, the Company's Chairman and Chief Executive Officer, commented, "We are all very disappointed with the outcome of this Study. While this represents the end of one chapter for Keryx, it is not the end of Keryx. Drug development is inherently risky and, accordingly, we have spent the last several years building what we believe to be a promising product portfolio in the event our lead drug failed. We plan to re-focus our primary efforts and resources on rapidly moving Zerenex forward for ESRD patients with hyperphosphatemia and Perifosine forward for cancer. Our goal is to have Perifosine in a pivotal program this year and be well into our Zerenex high- dose Phase 2 trial before the end of the year."

In order to participate in this morning's c
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
2. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
3. Keryx Biopharmaceuticals Announces Additions to Management Team
4. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
5. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
6. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
7. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
8. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
9. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
10. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
11. XTL Biopharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... BOSTON, MA (PRWEB) December 23, 2014 ... generation webinar series is designed to introduce ... and inform users and partners of platform ... features and benefits; empowering users in their ... and powerful tools. , According to SoundConnect’s ...
(Date:12/24/2014)... New York (PRWEB) December 23, 2014 According ... the Long Island Affiliate of ITRA Global, the national office ... but steady recovery. This is evidenced by the third ... strong stock market. Low energy costs have held inflation ... The only negative is the housing market remaining soft. , ...
(Date:12/24/2014)... Nashville, Tenn. (PRWEB) December 23, 2014 ... Hill was elected treasurer for the American Society ... to advancing knowledge and research in reproductive medicine. ... fills a seat on the executive board and will ... , Dr. Hill has actively supported ASRM since ...
(Date:12/24/2014)... San Diego, CA (PRWEB) December 23, 2014 ... Contest where their Twitter followers can submit their ... for themselves and their lab mates. , For those ... beloved lab mates, the Pipette.com Holiday in the Lab ... encourages Pipette.com Twitter followers to send pictures ...
Breaking Biology Technology:SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 3Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2
... CHERTSEY, England, Dec. 27, 2011  United Therapeutics Corporation ... subsidiary, United Therapeutics Europe, Ltd., announced today that ... Securite Sanitaire des Produits de Sante (AFSSAPS) ... the treatment of pulmonary arterial hypertension (PAH).  Remodulin ...
... WEST LAFAYETTE, Ind. Researchers have shown ... manipulate light in new ways that could make possible a ... and computers., The researchers ... property of light called its phase. Light is transmitted as ...
... 2011 In recognition of the International Year of Chemistry ... The Changing Role of Chemistry in Drug Discovery . ... with insights from industry experts, the new report forecasts the ... report suggests, a much more targeted, patient-specific approach will define ...
Cached Biology Technology:Intravenous Remodulin Approved for the Treatment of Pulmonary Arterial Hypertension in Most of the European Union 2Intravenous Remodulin Approved for the Treatment of Pulmonary Arterial Hypertension in Most of the European Union 3Intravenous Remodulin Approved for the Treatment of Pulmonary Arterial Hypertension in Most of the European Union 4Intravenous Remodulin Approved for the Treatment of Pulmonary Arterial Hypertension in Most of the European Union 5'Nanoantennas' show promise in optical innovations 2'Nanoantennas' show promise in optical innovations 3Thomson Reuters Research Forecasts the Onset of the Targeted Drug Discovery Era 2Thomson Reuters Research Forecasts the Onset of the Targeted Drug Discovery Era 3
(Date:12/17/2014)... Valencell, a leader in performance biometric data ... industry leaders such as Intel, Jabra, Atlas, and Scosche ... products. These products will be showcased at CES 2015, ... . "Our partners choose PerformTek ... – with the clinical data to back it up," ...
(Date:12/17/2014)... -- Automation is fundamentally transforming the travel experience and ... borders. Over the past decade, ePassports, biometric readers, ... to self process through border control via eGates ... increasing number of airports, seaports, and land borders ... Maxine Most , Principal at Acuity Market ...
(Date:12/11/2014)... --Research and Markets , ... ) has announced the addition of the ... to their offering. One major ... technology. With continuous advances in technology, it is ... standard that meets the needs and expectations of ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... crystallised a protein that may help gut bacteria bind to the ... identify strains that are likely to be of real benefit to ... to have a beneficial effect, and if they attach to surfaces ... enough to exert their activity," says Dr Nathalie Juge from the ...
... College of Medical Toxicology (ACMT) have signed an agreement to ... Toxicology (JMT), the official journal of the ACMT, beginning ... University of Pennsylvania Press. The Journal of ... advancing the science and practice of medical toxicology. The ...
... food is a matter of debate. A high-profile study a ... of their carbon from trees and leaves, evidence for a ... But new research from the University of Washington shows this ... richer diet for fish and other aquatic life, according to ...
Cached Biology News:A sticky solution for identifying effective probiotics 2Springer and the American College of Medical Toxicology to work together 2Fish food fight: Fish don't eat trees after all, says new study 2Fish food fight: Fish don't eat trees after all, says new study 3
... is the cycler that revolutionized thermal ... and swappable blocks ensure consistent results, ... rugged machine is more than just ... new features and upgrades as research ...
Request Info...
Peroxidase Protective Buffer is a diluent formulated to stabilize the activity of Chemicon horseradish peroxidase (HRP)-antibody conjugates at high conjugate dilution for extended periods....
... Soybean-Casein Digest Medium (TSB), USP is a ... for general laboratory use. Due to the ... the medium will support growth of many ... etc. , Product conforms to United States ...
Biology Products: